[go: up one dir, main page]

FI945556A0 - Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset - Google Patents

Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset

Info

Publication number
FI945556A0
FI945556A0 FI945556A FI945556A FI945556A0 FI 945556 A0 FI945556 A0 FI 945556A0 FI 945556 A FI945556 A FI 945556A FI 945556 A FI945556 A FI 945556A FI 945556 A0 FI945556 A0 FI 945556A0
Authority
FI
Finland
Prior art keywords
pct
aryl
date
sec
inflammatory
Prior art date
Application number
FI945556A
Other languages
English (en)
Swedish (sv)
Other versions
FI945556A (fi
Inventor
Edward F Kleinman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI945556A0 publication Critical patent/FI945556A0/fi
Publication of FI945556A publication Critical patent/FI945556A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI945556A 1993-11-26 1994-11-25 Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset FI945556A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15724193A 1993-11-26 1993-11-26

Publications (2)

Publication Number Publication Date
FI945556A0 true FI945556A0 (fi) 1994-11-25
FI945556A FI945556A (fi) 1995-05-27

Family

ID=22562909

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945556A FI945556A (fi) 1993-11-26 1994-11-25 Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset

Country Status (12)

Country Link
US (1) US5686434A (fi)
EP (1) EP0730587B1 (fi)
JP (1) JP2818820B2 (fi)
AT (1) ATE187447T1 (fi)
CA (1) CA2177375A1 (fi)
DE (1) DE69422061T2 (fi)
DK (1) DK0730587T3 (fi)
ES (1) ES2139754T3 (fi)
FI (1) FI945556A (fi)
GR (1) GR3032506T3 (fi)
PT (1) PT730587E (fi)
WO (1) WO1995014680A1 (fi)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990136A (en) * 1996-08-21 1999-11-23 Pharmacia & Upjohn Company Isoxazoline derivatives useful as antimicrobials
PT937075E (pt) * 1996-11-11 2004-05-31 Altana Pharma Ag Novas imidazo- e oxazolo-piridinas como inibidores da fosfodiesterese
EP0966452B1 (de) * 1997-01-17 2003-05-02 Basf Aktiengesellschaft Verfahren zur herstellung von schwefelhaltigen 2-chlor-3-(4,5-dihydroisoxazol-3-yl)-benzoesäuren
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
DE69902634T2 (de) * 1998-02-13 2003-04-24 Pharmacia & Upjohn Co., Kalamazoo Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien
CA2652071C (en) * 1998-05-11 2012-01-17 Basf Aktiengesellschaft Method for producing isoxazoline-3-yl-acyl benzene
DE19852095A1 (de) * 1998-11-12 2000-05-18 Basf Ag Verfahren zur Herstellung von 2-Alkyl-3-(4,5-dihydroisoxazol-3-yl)-acylbenzolen
DE69914931T2 (de) 1998-10-09 2004-12-16 Janssen Pharmaceutica N.V. 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
JP4195561B2 (ja) * 1999-09-17 2008-12-10 エルジー ケム インヴェストメント リミティッド カスパーゼインヒビター
KR100399361B1 (ko) 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
DE19953024A1 (de) * 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
KR100594544B1 (ko) 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
JP2007530598A (ja) * 2004-03-26 2007-11-01 サイトカイン・ファーマサイエンシズ・インコーポレーテッド マクロファージ遊走阻害因子の阻害に関する、化合物、組成物、作製プロセス、および使用方法
CN101006065B (zh) * 2004-06-17 2012-07-11 英菲尼蒂发现公司 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
ES2370788T3 (es) * 2005-02-07 2011-12-22 Aerocrine Ab Controlar flujo de aliento exhalado durante análisis.
WO2006097273A1 (en) * 2005-03-15 2006-09-21 Ganial Immunotherapeutics Inc. Compounds having immunomodulator activity
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
JP2010504323A (ja) * 2006-09-22 2010-02-12 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害物質
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MY163048A (en) 2009-05-06 2017-08-15 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
CN101781294B (zh) * 2010-03-10 2012-02-01 天津药物研究院 一类咪唑的衍生物、其制备方法和用途
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
CN103596936B (zh) 2011-03-31 2016-11-09 拜耳知识产权股份有限公司 具有除草和杀真菌活性的3‑苯基异噁唑啉‑5‑甲酰胺和3‑苯基异噁唑啉‑5‑硫代酰胺
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
AU2013322855B2 (en) 2012-09-25 2017-06-22 Bayer Cropscience Ag Herbicidal and fungicidal 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides
KR101977920B1 (ko) 2012-09-25 2019-05-13 바이엘 크롭사이언스 악티엔게젤샤프트 제초 작용을 가지는 3-페닐이속사졸린 유도체
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US11613522B2 (en) 2017-06-13 2023-03-28 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro- and dihydrofurancarboxamides
UA126240C2 (uk) 2017-06-13 2022-09-07 Баєр Акціенгезельшафт Гербіцидно активний 3-фенілізоксазолін-5-карбоксамід тетрагідро- та дигідрофуранкарбонових кислот та складних ефірів
BR112020003266A2 (pt) 2017-08-17 2020-10-13 Bayer Aktiengesellschaft 3-fenil-5-trifluorometilisoxazolina-5-carboxamidas herbicidamente ativas de ésteres e ácidos ciclopentilcarboxílicos
PL3743411T3 (pl) 2018-01-25 2023-03-13 Bayer Aktiengesellschaft Herbicydowo czynne 3-fenyloizoksazolino-5-karboksyamidy z pochodnych kwasów cyklopentenylokarboksylowych
WO2020182723A1 (de) 2019-03-12 2020-09-17 Bayer Aktiengesellschaft Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von s-haltigen cyclopentenylcarbonsäureestern
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JPS62103070A (ja) * 1985-10-29 1987-05-13 Mitsui Toatsu Chem Inc イソオキサゾリン誘導体および植物生長調節剤
US4912120A (en) * 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
ZA872997B (en) * 1986-05-09 1988-12-28 Warner Lambert Co Novel styryl pyrazoles,isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors,pharmaceutical compositions and methods of use therefor
DE3736113A1 (de) * 1987-10-26 1989-05-03 Hoechst Ag Arzneimittel, darin enthaltene phosphorhaltige 2-isoxazoline und isoxazole, sowie herstellungsverfahren fuer diese heterocyclischen verbindungen
US4952700A (en) * 1988-04-25 1990-08-28 W.R. Grace & Co.-Conn. Preparation of isoxazolines and isoxazoles
US4933464A (en) * 1988-04-25 1990-06-12 W. R. Grace & Co.-Conn. Process for forming 3-phenylisoxazolines and 3-phenylisoxazoles
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
DE4026018A1 (de) * 1990-08-17 1992-02-20 Hoechst Ag Isoxazoline oder isothiazoline enthaltende pflanzenschuetzende mittel und neue isoxazoline und isothiazoline
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
WO1993007141A1 (en) * 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production

Also Published As

Publication number Publication date
DE69422061T2 (de) 2000-03-30
FI945556A (fi) 1995-05-27
DE69422061D1 (de) 2000-01-13
PT730587E (pt) 2000-05-31
ES2139754T3 (es) 2000-02-16
DK0730587T3 (da) 2000-04-10
EP0730587A1 (en) 1996-09-11
US5686434A (en) 1997-11-11
CA2177375A1 (en) 1995-06-01
EP0730587B1 (en) 1999-12-08
ATE187447T1 (de) 1999-12-15
WO1995014680A1 (en) 1995-06-01
JP2818820B2 (ja) 1998-10-30
GR3032506T3 (en) 2000-05-31
JPH09500146A (ja) 1997-01-07

Similar Documents

Publication Publication Date Title
FI945556A0 (fi) Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset
FI945557A (fi) Isoksatsoliiniyhdisteet tulehduksenvastaisina aineina
DK0730579T3 (da) Substituerede indoler som inhibitorer af phosphodiesterase-type-IV
FI935379A0 (fi) Katekoldietrar som fungerar som selektiva PDEIV-inhibitorer
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
DK0980374T3 (da) Phosphodiesterase 4-inhiberende diazepinoindoloner.
DK0752990T3 (da) Benzisothiazolderivater som inhibitorer af 5-lipoxygenasebiosyntese
MY112586A (en) Isoxazoline compounds as 5-lipoxygenase inhibitors

Legal Events

Date Code Title Description
FD Application lapsed